Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

47
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
47
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

60
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
60
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

41
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
41
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

73
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
73
Pharmacodynamic Models: Emax Drug–Concentration Effect Model01:18

Pharmacodynamic Models: Emax Drug–Concentration Effect Model

81
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
81
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

322
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
322

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

SpatioTemporal Omics Consortium: a global effort for biological discovery across species, space and time.

Nature methods·2026
Same author

Segmentation and classification of hippocampal subregions using multi-task generative adversarial networks.

Scientific reports·2026
Same author

Deep learning multi-omics integration identifies new molecular subtypes of lung cancer.

BioData mining·2026
Same author

ExPO: an exposure-conditioned neural operator for L1000 signature prediction.

Journal of cheminformatics·2026
Same author

Population Analysis and Immunologic Landscape of Melanoma in People Living with HIV.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Early Sepsis Prediction Using Publicly Available Data: High-Performance AI/ML Models with First-Hour Clinical Information.

Diagnostics (Basel, Switzerland)·2025

相关实验视频

Updated: Feb 28, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.7K

GenReP:用于预测TP53对药物化合物的反应的整体模型.

Austin Spadaro1, Alok Sharma2,3,4, Iman Dehzangi1,5,6

  • 1Center for Computational and Integrative Biology, Rutgers University, Camden, NJ 08102, USA.

Molecules (Basel, Switzerland)
|February 27, 2026
PubMed
概括

这项研究引入了一种新的机器学习模型,用于预测药物如何影响TP53瘤抑制基因. 该工具通过理解基因表达变化,有助于开发新的癌症疗法.

关键词:
连接地图 连接地图这就是TP53的特点.集体分类器集体分类器功能提取 特性提取基因表达的基因表达方式

更多相关视频

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.0K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K

相关实验视频

Last Updated: Feb 28, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.7K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.0K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K

科学领域:

  • 基因组学就是基因组学.
  • 计算生物学 计算生物学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • TP53是一种关键的瘤抑制基因,调节细胞亡,DNA修复和基因组稳定性.
  • 在约一半的癌症中发现TP53突变,使其成为关键的治疗点.
  • 需要预测工具来评估药物对TP53基因表达的影响.

研究的目的:

  • 开发一个整体机器学习模型,用于预测TP53相对基因表达变化对药物化合物的反应.
  • 为药物调节TP53基因创造一种新的预测剂.

主要方法:

  • 利用了来自SMILES表示的分子指纹,描述符和基于支架的特征.
  • 将特征连接到单个向量中,用于模型输入.
  • 在连接地图 (CMap) 数据库中的新基准数据集上训练模型.
  • 使用合成少数人过量采样技术 (SMOTE) 解决了类不平衡问题.

主要成果:

  • 该模型实现了62.9%的准确性,93.9%的灵敏度,40.3%的特异性和0.39的马修斯相关系数 (MCC).
  • 证明了用于预测TP53基因调节的概念证明.
  • 预测器,源代码和数据集是公开的.

结论:

  • 开发的机器学习模型是预测药物诱导的TP53基因表达变化的新工具.
  • 这项工作为未来针对个性化癌症治疗和药物开发的研究提供了基础.
  • 预测因素和数据集的公开可用性有助于进一步的科学研究.